MAPT and Alzheimer disease: According to the latest NIA-AA research framework proposed by Jack and colleagues in AAIC 2023, it has been suggested to use a combination of plasma Aβ42/Aβ40 and plasma p-Tau rather than them alone to identify individuals with a high risk of AD.